The final tranche of the total $26m round was triggered upon fulfillment of pre-defined product development and regulatory program objectives.
Each of the original Series B investors participated in the 2nd tranche – including:
– 6 Dimensions Capital,
– Action Potential Venture Capital,
– Windham Venture Partners,
– Delta Capital,
– Purple Arch Ventures, and
– others.
The company intends to use the funds to advance its clinical programs for its implantable neuromodulation technology platform.
Led by Milton M. Morris, Ph.D., President & CEO, Neuspera Medical is a medical device company that leverages both exclusively licensed and proprietary power transfer techniques to engineer miniaturized neuromodulation technologies – sometimes referred to as bioelectronics medicines.
This technology platform will provide patients and physicians new, and potentially earlier treatment options that are less invasive and more adaptable.
FinSMEs
20/02/2019